Thomas Jefferson University

Jefferson Digital Commons
Department of Pharmacology and Experimental Department of Pharmacology and Experimental
Therapeutics Faculty Papers
Therapeutics
7-26-2021

Longitudinal evaluation of azithromycin and cytokine
concentrations in amniotic fluid following one-time oral dosing in
pregnancy.
Rupsa C. Boelig
Thomas Jefferson University

Edwin Lam
Thomas Jefferson University

Ankit Rochani
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/petfp

Gagan Kaushal

Part of
the Obstetrics
and Gynecology Commons, and the Pharmacy and Pharmaceutical Sciences
Thomas
Jefferson
University
Commons

Amanda Roman

Let
us
know
how access to this document benefits you
Thomas
Jefferson
University
Recommended Citation
See next page for additional authors
Boelig, Rupsa C.; Lam, Edwin; Rochani, Ankit; Kaushal, Gagan; Roman, Amanda; and Kraft, Walter
K., "Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid
following one-time oral dosing in pregnancy." (2021). Department of Pharmacology and
Experimental Therapeutics Faculty Papers. Paper 134.
https://jdc.jefferson.edu/petfp/134
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an
authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Rupsa C. Boelig, Edwin Lam, Ankit Rochani, Gagan Kaushal, Amanda Roman, and Walter K. Kraft

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/petfp/134

Received: 12 May 2021
DOI: 10.1111/cts.13111

|

Revised: 12 May 2021

|

Accepted: 16 May 2021

ARTICLE

Longitudinal evaluation of azithromycin and cytokine
concentrations in amniotic fluid following one-time oral dosing in
pregnancy
Rupsa C. Boelig1,2
Amanda Roman1

|

|

Edwin Lam2,3
Walter K. Kraft2

1

Division of Maternal Fetal Medicine,
Department of Obstetrics and
Gynecology, Sidney Kimmel Medical
College, Thomas Jefferson University,
Philadelphia, Pennsylvania, USA
2

Department of Clinical Pharmacology
and Experimental Therapeutics, Sidney
Kimmel Medical College, Thomas
Jefferson University, Philadelphia,
Pennsylvania, USA
3

Clinical Pharmacokinetics Research
Unit, Pharmacy Department, National
Institutes of Health, Bethesda, Maryland,
USA
4

College of Pharmacy, Thomas Jefferson
University, Philadelphia, Pennsylvania,
USA
Correspondence
Rupsa C. Boelig, Level 1 -Department of
Obstetrics and Gynecology, 833 Chestnut
St., Philadelphia, PA, USA.
Email: Rupsa.boelig@jefferson.edu
Funding information
This study was funded in part through an
E.W. Thrasher Early Investigator award
(PI R.C.B.). R.C.B. is supported by a
PhRMA Faculty Development Award.
W.K.K. is supported by T32GM008562
(PI W.K.K.).

|

Ankit Rochani4

|

Gagan Kaushal4

|

Abstract
To utilize noninvasive collection of amniotic fluid in the setting of preterm premature rupture of membranes (PPROMs) to report the time concentration profile of
azithromycin in amniotic fluid over 7 days from a single dose, and evaluate the correlation between azithromycin concentration and inflammatory markers in amniotic
fluid. Prospective cohort study of five pregnant patients admitted with PPROMs and
treated with a single 1 g oral azithromycin dose. Amniotic fluid was collected from
pads and used to quantify azithromycin concentration as well as TNFa, IL-1a, IL-
1b, IL-6, IL-8, and IL-10 concentrations. Primary outcome was time/concentration
profile of azithromycin in amniotic fluid. Secondary outcome included correlation
between azithromycin concentration and cytokine concentrations. Five patients were
enrolled. Mean gestational age on admission with PPROM was 27.5 ± 2.3 weeks with
a median latency of 7 days (interquartile range [IQR] = 4–13). A median of two samples/day (IQR = 1–3) were collected per participant. Azithromycin was quantified in
duplicate; intra-assay coefficient of variation was 17%. Azithromycin concentration
was less than 60 ng/ml after day 3. Azithromycin concentration was positively correlated with IL-8 (r = 0.38, p = 0.03), IL1a (r = 0.39, p = 0.03), and IL-1b (r = 0.36,
p = 0.04) in amniotic fluid. Azithromycin is detectable in amniotic fluid over 7 days
from a single 1 g maternal dose, however, it is not sustained over the range of minimum inhibitory concentration for common genitourinary flora. Based on correlation
with specific cytokines, azithromycin penetration in amniotic fluid may relate to maternal monocyte concentration in amniotic fluid in the setting of PPROM.
Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Azithromycin is used to prevent infection in setting of preterm premature rupture
of membranes (PPROMs), but there is no established dose. One cross-sectional
study with one patient found amniotic fluid azithromycin concentration was below
Presentations: This data was presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 15, 2021, as a poster.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
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minimum inhibitory concentration (MIC)50 of common genitourinary (GU) flora
7 days after a single 1 g maternal dose. There is no reported correlation between
maternal azithromycin treatment and the concentration of drug and inflammatory cytokines in amniotic fluid.
WHAT QUESTIONS DID THIS STUDY ADDRESS?
Our objective was to utilize noninvasive collection of amniotic fluid in pregnant patients admitted with PPROM to address whether one-time maternal dosing of azithromycin can produce a sustained amniotic fluid concentration greater than the MIC of
common GU flora over 7 days, and secondarily, whether amniotic fluid azithromycin
concentration was correlated with inflammatory cytokine concentrations.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Azithromycin is detectable in amniotic fluid over 7 days from a single 1 g maternal dose, however, it is not sustained over the range of MIC for common GU flora.
Azithromycin concentration in amniotic fluid is correlated with specific cytokines
that suggest that azithromycin penetration in amniotic fluid may relate to maternal
monocyte concentration in amniotic fluid in the setting of PPROM.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Amniotic fluid may be collected noninvasively from patients with PPROM and used
to evaluate the fetal environment, including medication penetrance and inflammatory
markers. Given the benefit of maternal and fetal exposure to azithromycin for prevention of adverse perinatal outcomes, it is important to study how maternal dosing
leads to azithromycin concentration within the maternal fetal unit in order to optimize
therapy.

I N T RO D U C T ION
Preterm birth complicates ~ 10% of pregnancies, is the leading cause of neonatal morbidity and mortality, and has rising incidence in the United States over the past 3 years.1
Preterm premature rupture of membranes (PPROMs) is responsible for ~ 25% of preterm births. Prior to 34 weeks’
gestation, PPROM is managed expectantly with the goal of
prolonging pregnancy, which is associated with improved
neonatal outcomes. Broad spectrum antibiotics increase
latency to delivery, reduce the rate of intra-amniotic infection, and improve neonatal morbidity.2,3 The historically
recommended regimen is i.v. erythromycin and ampicillin
for 48 h followed by p.o. erythromycin and amoxicillin for
5 days (total 7 day course).2 There is no consensus of optimal azithromycin dosing in PPROM and a variety of dosing regimens are used.4 Pharmacokinetic studies comparing
azithromycin dosing in pregnancy or the neonatal impact of
maternal dosing in PPROM are lacking, resulting in a critical gap in knowledge.
Azithromycin accumulates in phagocytes and is delivered in high concentration to sites of infection, which
is why it may be dosed infrequently and serum levels
alone do not reflect efficacy.5 The exact mechanism of
action by which macrolides in increased latency and reduced chorioamnionitis in PPROM is unclear. PPROM

is not always associated with specific bacterial infection,
although even in the absence of identified infection it is
generally an inflammatory condition and is associated
with both clinical (~ 15% incidence) and histologic inflammation, also known as chorioamnionitis (~ 60%).4
Most puerperal infections are polymicrobial and azithromycin is active against common genitourinary bacteria.
Immunomodulatory properties may also increase latency
to delivery by inhibiting inflammatory pathways, which
precipitate preterm birth.
Physiologic changes in pregnancy can impact a drug’s
pharmacokinetics (PKs), these changes include changes in
hepatic metabolism, significantly increased renal clearance,
significantly increased total body water, plasma volume, and
adipose content, all of which impact drug bioavailability.6
Azithromycin PKs, however, are not dependent on those systems. It is rapidly distributed from serum into intracellular
compartments, and ultimately to tissues. It has low serum
binding, and most of the absorbed drug remains unmetabolized within the body. Due to its PKs, serum concentrations
of azithromycin are not clinically relevant, rather its concentration at tissue of action is a better predictor of efficacy.7
Fetal exposure can be measured through cord blood, amniotic
fluid, and placental concentration. Concentration in umbilical cord blood alone may not be indicative of fetal exposure
for a medication like azithromycin where tissue distribution
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rapidly depletes serum concentrations.8,9 Given the important
role of intra-amniotic infection and inflammation in perinatal outcomes in preterm birth and PPROM, it is critical to
evaluate azithromycin concentration in the amniotic fluid
compartment.
Pregnancy-specific PKs of azithromycin are poorly defined.10 One study in pregnancy9 evaluated a single 1 g
p.o. azithromycin dose, but only had one participant with
data >3 days postdose. Azithromycin concentration was
above minimum inhibitory concentration (MIC)50 at day
3 but fell below MIC50 by day 7 (N = 1) in uterine myometrium, placenta, and amniotic fluid for genital C. trachomatis (MIC50 = 60 ng/ml),11 and Ureaplasma spp
(MIC50 = 500 ng/ml).12 Another study examining azithromycin PKs 8 h after a 500 g i.v. maternal dose found median
concentration in amniotic fluid was 33 ng/ml around 1 h postdose, well below MIC50 for ureaplasma.13 A primate model
found that compared to a one-time dose, daily dosing resulted
in sustained elevated azithromycin concentration in amniotic
fluid.14 Although these studies are limited in number, size,
and scope, they suggest that the one-time 1 g dosing of azithromycin commonly used may be suboptimal for a 1 week
therapy course in PPROM.
There are no established pharmacodynamic (PD) markers
of azithromycin therapy. In non-pregnant patients, azithromycin attenuates the expression of inflammatory cytokines
IL-6, IL-8, and TNFa, and enhances expression of IL-10,
an anti-inflammatory cytokine.5 In PPROM, earlier delivery,15 choriamnionitis,16,17 funisitis, and fetal inflammatory
response18,19 are associated with elevated inflammatory cytokines, especially IL-6 and IL-8, in maternal serum and amniotic fluid. Azithromycin may improve latency to delivery
through both antibacterial and immunomodulatory effects
and these cytokines are relevant biomarkers to study in evaluating azithromycin dosing.
Previous studies have demonstrated the ability to noninvasively sample amniotic fluid,18 and the correlation between
noninvasive sampling of amniotic fluid and invasive sampling with regard to inflammatory markers18,20 and microbial
invasion.20 Our objective was to utilize noninvasive collection of amniotic fluid in the setting of PPROM to report the
time concentration profile of azithromycin in amniotic fluid
over 7 days from a single dose, and evaluate the correlation
among azithromycin concentration, inflammatory markers in
amniotic fluid, and placental pathological markers, including
histologic chorioamnionitis. We chose to focus on amniotic
fluid azithromycin concentration because, unlike serum, it
reflects target site concentration, and unlike myometrium or
cord blood, it can be sampled throughout pregnancy, not just
at delivery. This allows for a longitudinal evaluation of azithromycin concentration at the site of action for a clinically
relevant PK model that can be used to guide dosing for the
purpose of improving perinatal outcomes.
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M ETHODS
Study design
This is a prospective, observational cohort study of pregnant patients admitted with PPROM at Thomas Jefferson
University Hospital from November 2019 to March 2020
who received azithromycin for latency. Azithromycin was
administered as part of standard clinical care. The only exclusion was non-English speaking, as translated consents were
not available. Recruitment for this effort stopped in March
2020 due to the coronavirus disease 2019 pandemic restrictions and then subsequent initiation of a randomized trial relating to PPROM (NCT04294069). All patients received a
standard of care dose of 1 g oral azithromycin once as part
of latency antibiotic regimen (in addition, patients received
i.v. ampicillin/oral amoxicillin). Participants were given
Always flex-foam pads (Proctor & Gamble) to line their underwear. As amniotic fluid leaked, they changed their pads
as per their comfort and pads were collected. Because pads
were collected per participant comfort rather than at timed
intervals, sample time points were grouped in 8-h windows
to allow comparison among participants. Amniotic fluid was
extracted from pads using a press, samples were centrifuged
at 1500 g for 10 min and stored at −80 degrees similar to
previous study.18 In addition, baseline characteristics, gestational age, latency to delivery, and delivery outcomes were
collected. All participants provided written consent and this
study was approved by Thomas Jefferson University institutional review board.

Azithromycin quantification
Liquid chromatography mass spectrometry (LCMS) analysis for standards and samples were performed using Thermo
Exactive Orbitrap coupled with Dionex 3000 HPLC system.
Mass spectrometry method was established in the scanning
mass range of 240 to 420 m/z, using Thermo Exactive Plus
Orbitrap mass spectrometer (Thermo Scientific). All the
scans were performed under positive ion mode and electron spray ionization. Sheath gas flow rate was maintained
at 20 psi; auxiliary gas flow was 5 psi; electron spray voltage used was 4 kV; and capillary temperature was 375°C.
Capillary, tube lens, and skimmer voltage were kept at 27.50,
65, and 16 V, respectively. These parameters were optimized
using Xcaliber software to get target mass intensity of 106 to
107 units, for azithromycin. The method was integrated with
the high-performance liquid chromatography HPLC method
to get method for LCMS runs.
Analysis was performed using Dionex Ultimate 3000
HPLC system (Thermo Fischer) attached to Thermo orbitrap
mass spectrometer. LCMS runs of calibration standard and
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isocratic elution with 50:50 (water with 0.1% formic acid
[FA]: acetonitrile [can] with 0.1% FA). All the samples and
standards injection volume were set to 5 µl and chromatographic separations were performed using HSS XSelect C18
reverse phase column (4.6 × 100 mm), Waters (Milford, MA)
at flow rate of 0.25 ml/min with run time of 5 min. Column
compartment and sampler temperature was set to 30 and 20°,
respectively. LCMS data (for samples and standards) was acquired and saved for further quantitative analysis.
Calibration curve was established using blank amniotic
fluid spiked with azithromycin. Primary stocks of azithromycin were made in the concentration range of 10 to 2000 ng/
ml in ACN. These primary stocks were spiked in the amniotic
fluid at a concentration range of 1 to 200 ng/ml with 100 µl
as final volume and azithromycin-D3 as an internal standard
at final concentration of 100 ng/ml. Extraction of azithromycin (from calibration spike standards and samples) was
performed using protein precipitation method, with amniotic
and ACN ratio as 1:2.
Azithromycin concentration in amniotic fluid was ascertained with LCMS. Mass spectrometry method was established in the scanning mass range of 240 to 420 m/z, using
Thermo Exactive Plus Orbitrap mass spectrometer (Thermo
Scientific). Analysis was performed using Dionex Ultimate
3000 HPLC system (Thermo Fischer) attached to Thermo
orbitrap mass spectrometer. The lower limit of detection and
quantitation was found to be 1 and 10 ng/ml, respectively.

Cytokine quantification
Samples were analyzed using the human Cytokine/
Chemokine Magnetic Bead Panel Millipore plates specific for the following analytes: TNF-α, IL-1α, IL-1β, IL-6,
IL-8, and IL-10. Samples were analyzed in duplicate by a
FlexMAP 3D (Luminex) and average value used. Standard
curves were generated for each cytokine, and median fluorescent intensities were transformed into concentrations by
six-point, nonlinear regression.
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correlation between these and histologic chorioamnionitis.
Correlation among azithromycin concentration, inflammatory markers, and histologic chorioamnionitis was evaluated
with Pearson correlation coefficient. The R package was
used for statistical analysis. Any p value less than 0.05 was
considered significant.

RESULTS
Five patients were enrolled, one set of twins (ID #1) and
four singleton gestations. Mean gestational age on admission
with PPROM was 27.5 ± 2.3 weeks and body mass index
32.8 ± 6.2 kg/m2 (Table 1). Mean gestational age at delivery was 28.7 ± 2.6 weeks with a median latency of 7 days
(interquartile range (IQR) = 4–13). Four (80%) patients had
histologic chorioamnionitis and one (20%) had clinical chorioamnionitis. Azithromycin was well-tolerated and there was
no treatment-related adverse event.

Sampling
A median of two samples/day (IQR = 1–3) were collected
per participant. Up to 10 cc of amniotic fluid per pad was
collected and stored; median sample volume was 6 cc (IQR
= 3–8). Azithromycin was successfully quantified in duplicate. Coefficient of variation between duplicates was 17%. In
examining variation within each day, overall, the coefficient
of variation (SD/mean) appeared to trend down after 48 h
(Table 2).
T A B L E 1 Baseline characteristics and delivery outcomes of
included participants with PPROM receiving 1 g azithromycin one
time on admission
Baseline characteristics
Race N (%)`
African American

3 (60)

White

1 (20)

Hispanic

1 (2)

Statistical analysis

Age

Because participants leaked fluid and changed the pads ad
lib, any sample collected 0–8 h was marked as 8 h postdose,
any sample collected 8–16 was marked as 16 h postdose and
so on, this allowed data to be grouped and analyzed across
participants. The primary outcome was to describe the concentration/time profile of azithromycin in amniotic fluid
over the course of 7 days from a single 1 g oral azithromycin
maternal dose. Secondary outcomes include the correlation
between azithromycin concentration and cytokines IL-1a, IL-
1b, IL-6, IL-8, IL-10, and TNF-α, as well as to examine the

BMI (kg/M )

32.8 ± 6.2

Gestational age on admission (weeks)

27.5 ± 2.3

Twin gestation

1 (20%)

30.8 ± 3.3
2

Delivery outcomes
Gestational age at delivery (weeks)

28.7 ± 2.6

Latency (days)

7 [4–13]

Histologic chorioamnionitis

4 (80)

Clinical chorioamnionitis

1 (20)

Note: Data presented as mean ± SD or median [IQR] or N (%).
Abbreviations: BMI, body mass index; IQR, interquartile range.
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N/A

27 ± 18

0.67

27 [10–45]

53 ± 22

0.42

54 [45–71]

DISCUSSION
Main findings
We have demonstrated a persistent, although declining, level
of azithromycin in amniotic fluid through 7 days from a single 1 g maternal dose. One gram of maternal azithromycin
dose did not maintain amniotic fluid concentrations above
MIC for common genitourinary (GU) bacteria through the
7-day sampling period. Azithromycin concentration was correlated with monocyte specific cytokine concentration, suggesting azithromycin penetration in amniotic fluid may be
related to maternal monocyte concentration in amniotic fluid
in the setting of PPROM.

Results in the context of what is known

Abbreviations: AZ, azithromycin; IQR, interquartile range.

Note: There were no samples collected 0–24 h for any participants so that data is not available (N/A). N = number of participants and n = total number of samples.

21 [7–42]
25 [21–41]
N/A
Median [IQR]

46 [18–102]

42 [19–97]

0.59
0.70
N/A
Coefficient of variation
(SD/mean)

0.94

0.77

27 ± 16
33 ± 23
53 ± 41
N/A
Mean ± SD

63 ± 59

Azithromycin concentration trended down and was less
than 60 ng/ml after day 3 (Figure 1a,b). Azithromycin concentration was positively correlated with IL-8 (r = 0.38,
p = 0.03), IL1a (r = 0.39, p = 0.03), and IL-1b (r = 0.36,
p = 0.04) in amniotic fluid (Figure 2). Azithromycin
concentration was not correlated with TNF-α (r = 0.30,
p = 0.07), IL-6 (r = −0.06, p = 0.75), or IL-10 (r = 0.23,
p = 0.2) concentration in amniotic fluid. Only IL1b
(r = 0.49, p = 0.004), TNF-α (r = 0.45, p = 0.009), and
IL-8 (r = 0.78, p < 0.001) were correlated with histologic
chorioamnionitis (Figure 3).

18

18

Day 6 (144–168 h)
N = 2, n = 6
Day 5 (120–144 h)
N = 3, n = 8
Day 4 (96–120 h)
N = 2, n = 6
Day 3 (72–96 h)
N = 4, n = 11
Day 2 (48–72 h)
N = 4, n = 9
Day 0
(0–24 h)

Day 1 (24–48 h)
N = 4, n = 9

|

Azithromycin pharmacokinetics and
pharmacodynamics

Amniotic fluid AZ
(ng/ml)

TABLE 2

Azithromycin concentration in amniotic fluid 1–7 days after a single 1 g oral azithromycin maternal dose

Day 7
(168–172 h)
N, n = 1

AZITHROMYCIN PENETRATION IN AMNIOTIC FLUID

Using a noninvasive technique, we have demonstrated reliable azithromycin quantification in amniotic fluid with a
coefficient of variation less than 20%, which is deemed acceptable by the US Food and Drug Administration’s (FDA’s)
standards.21 Our coefficient of variation each day postdose
was similar to that found by Ramsey et al. who used amniocentesis for sampling suggesting our technique for noninvasive sampling is reliable and comparable to amniocentesis.
Previous studies have described this noninvasive collection
technique for quantification of inflammatory markers and
demonstrated results were concordant with samples collected
by invasive amniocentesis.20 Our study builds on the work
of Ramsey et al. with increased sampling, longitudinal rather
than cross-sectional data, and more participants and more
samples greater than 3 days after dosing.9 This is the first
study to our knowledge that evaluates noninvasive collection
of amniotic fluid for both longitudinal azithromycin concentration, and correlation between drug concentration and inflammatory markers.

6
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F I G U R E 1 Azithromycin concentration in amniotic fluid following 1 g oral maternal dose in patients with preterm premature rupture of
membranes. (a) Individual azithromycin concentration/time plots (b) Azithromycin concentration/time plots for individual and aggregate with
azithromycin concentration averaged over a 24-h period

F I G U R E 2 Correlation between mean azithromycin concentration (ng/ml) and cytokine concentration (pg/ml) in amniotic. Linear regression
performed for azithromycin versus individual cytokine concentrations, p < 0.05 considered significant

Azithromycin efficacy is generally reported by its MIC.
Efficacy of azithromycin in PPROM is difficult to estimate
because there is no single bacteria targeted. Common GU
bacteria vary in reported MIC—C. trachomatis (30–125 ng/
ml), N. gonorrhoeae (16–60 ng/ml), Staphylococcus and
Streptococcus spp (64–
500 ng/ml), and Ureaplasma spp
(500 ng/ml). A single azithromycin dose was not sufficient
to maintain amniotic fluid concentrations above this entire
polymicrobial range of MIC.
Fetal exposure to any medication depends on placental
transfer. Substrates that are small, lipophilic, or uncharged,
are more likely to be able to passively diffuse from

maternal blood, across the placental interface, and be taken
into fetal circulation. In addition, there are active placental transporters that may either concentrate or diminish the
fetal exposure of any maternally administered medication.6
By the third trimester, amniotic fluid is produced primarily from fetal urinary excretion and respiratory excretion;
transudation from fetal skin and placenta are limited after
~ 22–24 weeks. Fetal swallowing and reabsorption of any
drug in amniotic fluid can lead to increased fetal accumulation of drug.
It is notable, that while azithromycin is undetectable
in maternal serum after 4–7 days after a single dose,9 it
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F I G U R E 3 Correlation between
amniotic fluid IL-8 concentration and
histologic chorioamnionitis

persists in amniotic fluid. Amniotic fluid is an active tissue
and plays an important role in innate and cellular immunity. Although monocytes and neutrophils are almost undetectable in the amniotic fluid of a normal pregnancy, they
are increased in the setting of PPROM and intra-amniotic
infection.22,23 Azithromycin accumulates in phagocytes,
therefore, intra-amniotic infection or inflammation may
be associated with a higher amniotic fluid azithromycin
concentration due to increased monocyte localization.
One study of pregnant women found that amniotic fluid
monocytes were increasingly of maternal origin as intra-
amniotic infection progresses.24 Notably, the same investigators found that monocytes in amniotic fluid primarily
produced IL1-a, IL-1b, and IL-8,23 which we also found
were the cytokines correlated with higher azithromycin
concentration in amniotic fluid. Thus, in this setting, fetal
exposure to azithromycin may relate primarily to maternal
monocyte transfer into amniotic fluid rather than more traditional mechanisms of placental drug transfer.
Our data are not sufficient to establish PD markers of
azithromycin therapy. We are unable to differentiate cause/
effect—do higher inflammatory markers imply increased
inflammation, increased monocytes, and therefore increased azithromycin concentration? Will this eventually
result in reduced inflammatory markers? The reported
anti-inflammatory effect of azithromycin is a secondary effect and not as a first-line effect. Further study needs to be
done on how azithromycin concentration in the fetal compartment impacts inflammatory pathways and pregnancy
outcome.

Research implications
A better understanding of the disposition over time of
azithromycin in the maternal/fetal compartment is critical to
better understanding its use, especially in the situations of
cervical insufficiency and PPROM, where the goal is to reduce inflammation, reduce the rate of chorioamnionitis, and
increase latency to delivery. Further study should be done to
evaluate the interaction between azithromycin concentration
and amniotic fluid inflammatory markers, which have been
associated with both maternal and neonatal outcomes; these
markers are potential PD indicators for azithromycin therapy
and/or prognostic indicators for outcome. Additionally, it is
critical to evaluate how maternal azithromycin dosing impacts fetal exposure and potentially neonatal outcomes, including risk of respiratory illness,25–27 in order to determine
appropriate maternal azithromycin dosing.

Clinical implications
Azithromycin is used routinely in PPROM, but is also being
studied in other high-risk pregnancy conditions, including
cervical insufficiency,28 prevention of maternal/neonatal sepsis,29 and perioperative prophylaxis.30 A better understanding of azithromycin disposition in the maternal fetal unit
would allow for rational dosing strategies for each of these
conditions. The commonly used single 1 g maternal azithromycin dose may not be optimal to maintain MIC antibiotic
concentration for the expected 7-day course in the setting of

8
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PPROM. Pharmacometric modeling approaches quantitate
drug exposure to PK response, and the data presented here
could inform generation of optimized dosing regimens using
PK/PD simulations.

above MIC for many common GU pathogens over 7 days.
Azithromycin concentration in amniotic fluid along with inflammatory markers may be used to compare dosing regimens and select one that optimizes concentration of drug at
the site of action.

Strengths and limitations

CONFLICT OF INTEREST
The authors declared no competing interests for this work.

This study has a number of strengths. We used noninvasive
sampling to study azithromycin PKs in the population of interest, those with PPROM, for whom serial amniocentesis may
not be feasible. Furthermore, given the inflammatory state of
PPROM and the unique nature of azithromycin to concentrate locally, PK studies on pregnant healthly women at term
may not be applicable to a patients with preterm PPROM.
This is the only study we could identify with longitudinal
sampling of multiple participants over 7 days following maternal azithromycin dosing. We focused on azithromycin
concentration in the amniotic fluid as this may be most clinically relevant for evaluating its efficacy.
There are also a number of limitations, the sample size is
limited, which does not allow for any conclusions regarding
azithromycin concentration, inflammatory milieu, and clinical
outcomes. Given the sparse opportunistic sampling, there were
no samples available for the first 24 h postdose when azithromycin concentration would be expected to peak9 thus we could not
report maximum plasma concentration (Cmax), time to Cmax
(Tmax), area under the curve (AUC), or clearance. Traditional
PK parameters, such as Cmax and Tmax for azithromycin in
pregnancy have previously been reported.9,13 We were interested in the trough levels, as maintaining levels above MIC for
7 days is what is clinically important for azithromycin dosing in
PPROM. Only one dosing regimen was used, thus doses cannot
be compared. Due to additional azithromycin dosing prior to
cesarean delivery in the setting of PPROM,31 it was not possible to universally evaluate placental or cord blood azithromycin
concentrations from initial azithromycin dosing on admission.
It is possible that leakage of urine was captured, however, this is
unlikely given our values are similar to prior reported concentration of azithromycin in amniotic fluid and over 200-fold less
than what is observed in maternal urine.9

CO NC LU S IO N
Amniotic fluid may be collected noninvasively from patients
with PPROM and used to evaluate the fetal environment,
including medication penetrance and inflammatory markers. This is particularly important when evaluating therapies
aimed at the maternal/fetal unit (uterus/placenta/membranes/
amniotic fluid/fetus), as many interventions for prevention
of preterm birth and puerperal infection are. A single dose of
azithromycin does not maintain amniotic fluid concentration
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